MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2023

Conditions
Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Interventions
BIOLOGICAL

Hematopoietic Allogeneic Stem Cells

HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cornell University

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Michio Hirano, MD

OTHER